Psoriasis Treatment Center of Central New Jersey
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks
Inclusion Criteria: 1. Male or female adult ≥ 18 years of age; 2. Diagnosis of chronic plaque-type 3. Psoriasis affecting 2%-10% BSA 4. Patient is being treated with biologic therapy for a minimum of 24 weeks 5. Able and willing to give written informed consent prior to performance of any study-related procedures Exclusion Criteria: 1. Psoriasis affecting ˂2% or \>10% BSA 2. Patient not receiving a biologic agent, or receiving biologic agent \<24weeks 3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit. 4. Has previously used DUOBRII
duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
Verify or correct the compensation shown for this listing.